Clinical Trial Update: Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

View source ↗

Summary

A clinical trial is evaluating immunoglobulin therapy to prevent or treat acquired hypogammaglobulinemia following CAR-T cell therapy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogammaglobulinemia Acquired

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: University of Alberta | Conditions: Hypogammaglobulinemia, Acquired | Status: RECRUITING